Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Gary Cutter et al.|The Lancet Neurology|2020Cited by 104
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteriaAndrew Solomon, Brian G. Weinshenker, Roman Pettigrew et al.|Multiple Sclerosis Journal|2020Cited by 68
Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosisSylvia Klineova, Stephen Krieger, Rebecca Straus Farber et al.|Multiple Sclerosis Journal - Experimental Translational and Clinical|2016Cited by 13
Objective and subjective measures of dalfampridine efficacy in clinical practiceSylvia Klineova, Stephen Krieger, Joshua Friedman et al.|Multiple Sclerosis Journal - Experimental Translational and Clinical|2018Cited by 4
Dalfampridine Real World Utilization and Efficacy Assessment (P7.244)Sylvia Klineova, Stephen Krieger, Joshua Friedman et al.|Neurology|2014Cited by 1